Isis Pharmaceuticals, Inc. Expands Use of BioClinica, Inc.'s Express EDC

Published: Sep 06, 2012

NEWTOWN, Pa.--(BUSINESS WIRE)--BioClinica®, Inc. (NASDAQ: BIOC), a leading global provider of clinical trial management solutions, announced today that Isis Pharmaceuticals will expand its current use of BioClinica’s Express Electronic Data Capture (EDC) solution to several upcoming trials. Isis is a global leader in antisense drug development with a broad pipeline of drugs that are applicable to many different disease targets. Isis's antisense technology provides a direct route from genes to drugs with the opportunity to dramatically improve industry drug discovery productivity.

Back to news